eTheRNA immunotherapies 
Welcome,         Profile    Billing    Logout  
 1 Product   7 Diseases  1 Product   0 Trials   14 News 
2 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
TriMix-DC (ex-vivo autologous dendritic cells vaccine) / eTheRNA immunotherapies
2013-000795-15: An open-label pilot clinical trial of MAGE-A3 and MAGE-C1 mRNA electroporated autologous dendritic cell vaccination in combination with lenalidomide maintenance therapy for multiple myeloma after first-line autologous stem cell transplantation.

Ongoing
2
20
Europe
TriMix-DC, TriMix-DC, Solution for injection/infusion in pre-filled syringe, Capsule, hard, REVLIMID 5 and 10 mg
UZ Brussel, UZ Brussel
Symptomatic Multiple Myeloma after first-line autologous stem cell transplantation, Symptomatic Multiple Myeloma after first-line autologous stem cell transplantation, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2011-001410-33: Randomized phase II clinical trial on mRNA electroporated autologous dendritic cells for stage III/IV melanoma in patients who are free from measurable tumor lesions following the local treatment of macro metastases

Ongoing
2
88
Europe
TriMix-DC, TriMix-DC, Solution for injection/infusion in pre-filled syringe
UZ BRUSSEL, UZ BRUSSEL
stage III/IV melanoma in patients who are free from measurable tumor lesions following the local treatment of macro metastases, stage III/IV melanoma in patients who are free from measurable tumor lesions following the local treatment of macro metastases, Diseases [C] - Cancer [C04]
 
 
ECI-006 / eTheRNA immunotherapies
No trials found
mRNA cancer immunotherapeutic / eTheRNA immunotherapies, Mymetics
No trials found
CoV-2 mRNA Vaccine / eTheRNA immunotherapies
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
TriMix-DC (ex-vivo autologous dendritic cells vaccine) / eTheRNA immunotherapies
2013-000795-15: An open-label pilot clinical trial of MAGE-A3 and MAGE-C1 mRNA electroporated autologous dendritic cell vaccination in combination with lenalidomide maintenance therapy for multiple myeloma after first-line autologous stem cell transplantation.

Ongoing
2
20
Europe
TriMix-DC, TriMix-DC, Solution for injection/infusion in pre-filled syringe, Capsule, hard, REVLIMID 5 and 10 mg
UZ Brussel, UZ Brussel
Symptomatic Multiple Myeloma after first-line autologous stem cell transplantation, Symptomatic Multiple Myeloma after first-line autologous stem cell transplantation, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2011-001410-33: Randomized phase II clinical trial on mRNA electroporated autologous dendritic cells for stage III/IV melanoma in patients who are free from measurable tumor lesions following the local treatment of macro metastases

Ongoing
2
88
Europe
TriMix-DC, TriMix-DC, Solution for injection/infusion in pre-filled syringe
UZ BRUSSEL, UZ BRUSSEL
stage III/IV melanoma in patients who are free from measurable tumor lesions following the local treatment of macro metastases, stage III/IV melanoma in patients who are free from measurable tumor lesions following the local treatment of macro metastases, Diseases [C] - Cancer [C04]
 
 
ECI-006 / eTheRNA immunotherapies
No trials found
mRNA cancer immunotherapeutic / eTheRNA immunotherapies, Mymetics
No trials found
CoV-2 mRNA Vaccine / eTheRNA immunotherapies
No trials found

Download Options